Arcellx executive sells over $327k in stock, buys shares at lower price https://www.investing.com/news/company-news/arcellx-executive-sells-over-327k-in-stock-buys-shares-at-lower-price-93CH-3518049
Arcellx director Patel Kavita sells shares worth over $84k https://www.investing.com/news/company-news/arcellx-director-patel-kavita-sells-shares-worth-over-84k-93CH-3516269
Arcellx''s Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market Arcellx is advancing Anito-cel in a pivotal Phase 2 trial, showing promising early results. Read why I recommend continuing to buy ACLX stock here.
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials. The collaboration with Kite enhances Arcellx's operational capabilities and financial stability, supporting the development of Anito-cel.
Arcellx executive sells over $1.1 million in company stock https://www.investing.com/news/company-news/arcellx-executive-sells-over-11-million-in-company-stock-93CH-3485638
Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX) Insider Sale: CFO Michelle Gilson Sells Shares of Arcellx Inc (ACLX)
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024 Arcellx (NASDAQ: ACLX ) just reported results for the first quarter of 2024. Arcellx reported earnings per share of -14 cents. This was above the analyst estimate for EPS of -51 cents. The company reported revenue of $39.26 million. This was 89.92% better than the analyst estimate for revenue of $20.67 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago.
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.